멜록시캄(Meloxicam) 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global meloxicam market looks promising with opportunities in the rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, and post-operative pain markets. The global meloxicam market is expected to grow with a CAGR of 8.8% from 2025 to 2031. The major drivers for this market are the increasing prevalence of chronic inflammatory diseases, the rising demand for non-steroidal anti-inflammatory drugs, and the growing awareness of pain management solutions.

• Lucintel forecasts that, within the type category, by dosage form is expected to witness the highest growth over the forecast period.
• Within the application category, rheumatoid arthritis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Meloxicam Market

The meloxicam market is witnessing several emerging trends, which are driven by the need for enhanced patient care, a focus on safety, and the proliferation of generic alternatives. These trends reflect a shift from traditional oral tablets to more diverse and targeted formulations, as well as an increased focus on non-opioid pain management solutions.

• Advanced Drug Delivery Systems: A prominent trend is the development of advanced drug delivery systems, such as extended-release tablets and topical gels. These innovations aim to improve patient compliance by reducing dosing frequency and minimizing systemic side effects, particularly gastrointestinal issues. This provides a more convenient and safer treatment option for long-term management of chronic conditions like arthritis.
• Non-Opioid Pain Management: A key trend is the positioning of meloxicam as a primary non-opioid alternative for acute and post-operative pain. New fast-acting formulations, including intravenous injections, are being developed and approved to provide effective pain relief without the risks of addiction and side effects associated with opioids. This trend directly addresses the global opioid crisis.
• Growth of Generic Formulations: The market continues to be shaped by the increasing prevalence of generic meloxicam. Following the patent expiration of branded products, numerous manufacturers have introduced low-cost alternatives. This trend has intensified price competition, making meloxicam more accessible to a wider patient population and expanding its market share, especially in developing economies.
• Combination Therapies: Another emerging trend is the research and development of combination therapies involving meloxicam. This involves combining meloxicam with other active ingredients to target multiple aspects of pain and inflammation simultaneously. Such strategies aim to improve therapeutic outcomes and offer a more comprehensive treatment approach, particularly for complex inflammatory conditions.
• Expansion into Veterinary Medicine: A notable trend is the growing application of meloxicam in veterinary medicine. As a safe and effective non-steroidal anti-inflammatory drug (NSAID) for animals, meloxicam is increasingly used to manage pain and inflammation in companion animals and livestock. This application presents a new growth avenue for the market, driven by the increasing focus on animal health.

These trends are fundamentally reshaping the meloxicam market by expanding its applications beyond traditional arthritis treatment, offering safer and more convenient formulations, and increasing accessibility through generic competition. The market is moving towards more specialized, application-specific products that cater to the evolving needs of both human and veterinary healthcare.

Recent Developments in the Meloxicam Market

The meloxicam market has seen a number of key developments driven by innovations in drug delivery and a strong focus on patient safety and convenience. These advancements are aimed at addressing evolving healthcare needs, particularly in chronic pain management and post-operative care, and are impacting the competitive landscape and product offerings globally.

• Fast-Acting IV Formulation: A significant development is the approval and market availability of a new intravenous (IV) formulation of meloxicam for moderate-to-severe acute pain. This fast-acting non-opioid injectable offers a crucial alternative for post-surgical pain management, helping to reduce reliance on opioids. Its introduction is particularly impactful in hospital settings, where a rapid onset of action is essential.
• Extended-Release Tablets: Another key development is the introduction of extended-release meloxicam tablets. These formulations are designed to provide sustained pain relief over a 24-hour period with a single daily dose. This improves patient adherence, reduces dosing frequency, and helps to minimize the risk of gastrointestinal side effects, making it a more convenient option for long-term management of chronic arthritis.
• Growing Generic Competition: The market has experienced a surge in generic competition following the expiration of key patents. This development has led to a reduction in the average price of meloxicam, making it more affordable and accessible to a wider patient population. While this puts pressure on the pricing of branded products, it also drives market volume and expands the drug's overall use.
• Topical Gels for Localized Pain: The development and introduction of topical meloxicam gels represent a significant advancement for treating localized pain. These gels allow for direct application to the affected area, providing targeted relief while reducing systemic exposure and the associated side effects. This formulation is particularly beneficial for patients with conditions like osteoarthritis in specific joints.
• Strategic Partnerships and Acquisitions: Pharmaceutical companies are engaging in strategic partnerships and acquisitions to expand their meloxicam product portfolios and geographical reach. These collaborations, particularly with generic manufacturers and companies specializing in new drug delivery technologies, are accelerating market growth, fostering innovation, and helping companies to gain a competitive edge.

These developments are having a profound impact on the meloxicam market by diversifying product offerings, enhancing patient safety and convenience, and increasing market accessibility. The market is shifting from a reliance on traditional oral tablets to a more diverse range of formulations that cater to specific patient needs, from acute post-operative pain to chronic arthritis management.

Strategic Growth Opportunities in the Meloxicam Market

The meloxicam market offers several strategic growth opportunities, driven by its versatile applications and the increasing demand for effective, non-opioid pain management solutions. These opportunities are focused on expanding into new therapeutic areas, developing innovative formulations, and catering to specific patient populations, thereby enhancing market penetration and value.

• Post-Operative Pain Management: A significant growth opportunity lies in positioning meloxicam as a first-line non-opioid alternative for post-operative pain. The development of fast-acting intravenous formulations allows for immediate pain relief in a clinical setting, reducing the need for addictive opioids. This is a high-growth area, driven by global efforts to mitigate the opioid crisis.
• Topical Formulations for Arthritis: The growing demand for non-systemic treatments for localized pain presents a key opportunity for topical meloxicam gels and creams. These formulations can provide targeted relief for conditions like osteoarthritis, minimizing the risk of systemic side effects. This application addresses a large patient population seeking a safer alternative to oral NSAIDs.
• Combination Therapies for Chronic Pain: Developing meloxicam-based combination therapies offers a strategic opportunity to create more potent and comprehensive pain management solutions. By combining meloxicam with other analgesics or anti-inflammatory agents, companies can offer multi-modal pain relief, which is particularly effective for managing chronic conditions that do not respond to a single medication.
• Veterinary Applications: The veterinary pharmaceutical sector represents a promising growth opportunity for meloxicam. As pet ownership and animal healthcare expenditure rise, there is increasing demand for effective and safe pain and inflammation management in animals. Meloxicam's established efficacy makes it a strong candidate for this expanding market segment.
• Formulations for Pediatrics: A niche but important opportunity exists in developing pediatric-specific meloxicam formulations. With the approval of meloxicam for juvenile rheumatoid arthritis, there is a need for child-friendly dosage forms, such as suspensions or chewable tablets. This would address a significant unmet need and expand the drug's market to a younger patient population.

These growth opportunities are impacting the meloxicam market by driving innovation beyond its traditional use. By focusing on these strategic areas, companies can differentiate their products, capture new market segments, and ultimately solidify meloxicam's position as a versatile and essential non-opioid medication in a wide range of applications.

Meloxicam Market Driver and Challenges

The meloxicam market is a dynamic landscape shaped by various drivers that propel its growth and a set of challenges that can hinder its progress. The key drivers are rooted in global demographic shifts and the pressing need for safer pain management, while challenges arise from regulatory scrutiny and intense market competition.

The factors responsible for driving the meloxicam market include:

1. Rising Prevalence of Arthritis: The increasing global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population, is a primary driver. Meloxicam is a widely prescribed NSAID for these conditions, and as the number of patients grows, so does the demand for the drug. This demographic shift provides a solid foundation for market expansion.

2. Preference for Non-Opioid Pain Relief: A major driver is the global effort to combat the opioid crisis. Healthcare providers and patients are increasingly seeking effective non-opioid alternatives for both chronic and acute pain management. Meloxicam, with its established efficacy and favorable safety profile compared to opioids, is well-positioned to meet this demand.

3. Patent Expirations and Generic Growth: The expiration of key patents has led to a proliferation of generic meloxicam products. This has made the drug more affordable and accessible, particularly in emerging markets. The resulting increase in market volume and competition is a significant driver of overall market growth.

4. Technological Advancements: Innovations in drug delivery systems, such as extended-release and intravenous formulations, are driving market growth. These advancements improve patient convenience, efficacy, and safety, making meloxicam a more attractive option for a wider range of applications, including post-operative care.

5. Growing Healthcare Expenditure: The rise in global healthcare expenditure, particularly in emerging economies, is a key driver. Increased spending allows for better access to medications and advanced treatments, thereby boosting the demand for meloxicam and other anti-inflammatory drugs.

Challenges in the meloxicam market are:

1. Side Effect Profile: Meloxicam, like all NSAIDs, carries a risk of side effects, including gastrointestinal and cardiovascular issues. These safety concerns can limit its use in certain patient populations and necessitate careful monitoring, which poses a significant challenge to market growth.

2. Competition from Alternatives: The market is highly competitive, not only from generic versions of meloxicam but also from other NSAIDs, biologics, and novel pain therapies. Differentiating meloxicam and its new formulations in a crowded market and maintaining market share is a continuous challenge for manufacturers.

3. Strict Regulatory Environment: The development and approval of new meloxicam formulations face a stringent regulatory environment. Regulatory bodies require extensive clinical data to prove efficacy and safety, which can be a costly and time-consuming process. This creates a barrier to entry for new products and slows down innovation.

The meloxicam market is being propelled by the growing need for effective, safe, and affordable pain management solutions, driven by an aging population and the fight against the opioid crisis. However, these positive trends are tempered by the inherent safety concerns associated with NSAIDs, intense market competition, and the challenging regulatory landscape that new formulations must navigate to reach the market.

List of Meloxicam Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies meloxicam companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the meloxicam companies profiled in this report include-

• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

Meloxicam Market by Segment

The study includes a forecast for the global meloxicam market by type, application, and region.

Meloxicam Market by Type [Value from 2019 to 2031]:

• by Ingredient
• by Route
• by Dosage Form

Meloxicam Market by Application [Value from 2019 to 2031]:

• Rheumatoid Arthritis
• Osteoarthritis
• Soft Tissue Inflammation
• Traumatic Pain
• Post-Operative Pain
• Others

Country Wise Outlook for the Meloxicam Market

The meloxicam market is undergoing significant transformations, driven by a growing aging population and rising prevalence of chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis. This has spurred a shift towards new formulations and a greater emphasis on non-opioid pain management. The market is also heavily influenced by generic competition and regional regulatory dynamics, shaping pricing and market access globally.

• United States: The U.S. market is highly competitive, with a strong presence of both branded and generic meloxicam. A key development is the focus on new, fast-acting formulations, such as those for intravenous use, aimed at managing moderate-to-severe acute pain. These innovations offer a non-opioid alternative for post-operative care, addressing the national opioid crisis and meeting demand for safer pain management.
• China: The Chinese meloxicam market is experiencing rapid growth, fueled by the country's expanding healthcare infrastructure and a large, aging population. Local and international companies are increasing their presence, with a focus on producing and distributing cost-effective generic versions. This expansion is supported by government initiatives to improve healthcare access and manage the rising burden of chronic diseases.
• Germany: Germany represents a mature European market for meloxicam, characterized by a well-established healthcare system and a strong emphasis on quality and safety. The market is driven by the management of chronic conditions, with a steady demand for both oral and injectable formulations. Regulatory standards and reimbursement policies play a crucial role in shaping market dynamics and product availability.
• India: India is a fast-growing market, primarily dominated by generic meloxicam products due to their affordability. The market is propelled by a large patient base with inflammatory conditions and a growing middle class with increasing access to healthcare. Pharmaceutical companies are focusing on low-cost manufacturing and expanding their distribution networks to cater to this high-demand, price-sensitive market.
• Japan: The Japanese market is defined by its focus on technological advancements and high-quality pharmaceutical products. While the market for meloxicam is steady, there is a strong emphasis on developing and utilizing advanced drug delivery systems and formulations to improve efficacy and reduce side effects. This reflects Japan's patient-centric approach to healthcare and its advanced geriatric care needs.

Features of the Global Meloxicam Market

• Market Size Estimates: Meloxicam market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Meloxicam market size by type, application, and region in terms of value ($B).
• Regional Analysis: Meloxicam market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the meloxicam market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the meloxicam market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the meloxicam market by type (by ingredient, by route, and by dosage form), application (rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, post-operative pain, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Meloxicam Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 by Ingredient: Trends and Forecast (2019-2031)
• 4.4 by Route: Trends and Forecast (2019-2031)
• 4.5 by Dosage Form: Trends and Forecast (2019-2031)

5. Global Meloxicam Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Rheumatoid Arthritis: Trends and Forecast (2019-2031)
• 5.4 Osteoarthritis: Trends and Forecast (2019-2031)
• 5.5 Soft Tissue Inflammation: Trends and Forecast (2019-2031)
• 5.6 Traumatic Pain: Trends and Forecast (2019-2031)
• 5.7 Post-Operative Pain: Trends and Forecast (2019-2031)
• 5.8 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Meloxicam Market by Region

7. North American Meloxicam Market

• 7.1 Overview
• 7.2 North American Meloxicam Market by Type
• 7.3 North American Meloxicam Market by Application
• 7.4 United States Meloxicam Market
• 7.5 Mexican Meloxicam Market
• 7.6 Canadian Meloxicam Market

8. European Meloxicam Market

• 8.1 Overview
• 8.2 European Meloxicam Market by Type
• 8.3 European Meloxicam Market by Application
• 8.4 German Meloxicam Market
• 8.5 French Meloxicam Market
• 8.6 Spanish Meloxicam Market
• 8.7 Italian Meloxicam Market
• 8.8 United Kingdom Meloxicam Market

9. APAC Meloxicam Market

• 9.1 Overview
• 9.2 APAC Meloxicam Market by Type
• 9.3 APAC Meloxicam Market by Application
• 9.4 Japanese Meloxicam Market
• 9.5 Indian Meloxicam Market
• 9.6 Chinese Meloxicam Market
• 9.7 South Korean Meloxicam Market
• 9.8 Indonesian Meloxicam Market

10. ROW Meloxicam Market

• 10.1 Overview
• 10.2 ROW Meloxicam Market by Type
• 10.3 ROW Meloxicam Market by Application
• 10.4 Middle Eastern Meloxicam Market
• 10.5 South American Meloxicam Market
• 10.6 African Meloxicam Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Meloxicam Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Boehringer Ingelheim
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Baudax
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Perrigo
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Recro Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Iroko Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Zyla Life Sciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Axsome Therapeutics
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Orbis Biosciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Cellix Bio
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Ligand Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us